Melatonin Supplementation for Children with Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial

JAMA Pediatrics

Volumn 170, Issue 1, 2016, Pages 35-42

  Chang, Yung Sen ^a,b,c   Lin, Ming Hung ^d   Lee, Jyh Hong ^e   Lee, Pei Lin ^e   Dai, Yang Shia ^e   Chu, Kuan Hua ^e   Sun, Chi ^e   Lin, Yu Tsan ^e   Wang, Li Chieh ^e   Yu, Hsin Hui ^e   Yang, Yao Hsu ^e   Chen, Chun An ^e   Wan, Kong Sang ^a   Chiang, Bor Luen ^b,e  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CARDINAL TIEN HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; IMMUNOGLOBULIN E; MELATONIN; PLACEBO; 6-SULFATOXYMELATONIN; BIOLOGICAL MARKER; CENTRAL DEPRESSANT AGENT;

ABSENCE OF SIDE EFFECTS; ACTIMETRY; ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CHILD; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTCOME ASSESSMENT; PEDIATRIC WARD; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING ATOPIC DERMATITIS INDEX; SKIN DISEASE ASSESSMENT; SLEEP DISORDER; SLEEP PATTERN; SLEEP TIME; TERTIARY CARE CENTER; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; INFANT; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; SLEEP; SLEEP WAKE DISORDERS; TREATMENT OUTCOME; URINE;

ADOLESCENT; BIOMARKERS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN E; INFANT; MALE; MELATONIN; POLYSOMNOGRAPHY; SEVERITY OF ILLNESS INDEX; SLEEP; SLEEP WAKE DISORDERS; TREATMENT OUTCOME;

EID: 84954174730     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2015.3092     Document Type: Article

References (34)

1. Bieber T. Atopic dermatitis. N Engl J Med. 2008; 358(14):1483-1494.
2. Camfferman D, Kennedy JD, GoldM, Martin AJ, Lushington K. Eczema and sleep and its relationship to daytime functioning in children. Sleep Med Rev. 2010;14(6):359-369.
3. Ricci G, Bendandi B, Bellini F, Patrizi A, Masi M. Atopic dermatitis: quality of life of young Italian children and their families and correlation with severity score. Pediatr Allergy Immunol. 2007;18(3): 245-249.
4. Lewis-Jones S. Quality of life and childhood atopic dermatitis: themisery of living with childhood eczema. Int J Clin Pract. 2006;60(8): 984-992.
5. Hon KL, Lam MC, Leung TF, Chow CM,Wong E, Leung AK. Assessing itch in children with atopic dermatitis treated with tacrolimus: objective versus subjective assessment. Adv Ther. 2007;24(1):23-28.
6. Leo HL, Bender BG, Leung SB, Tran ZV, Leung DY. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol. 2004;114 (3):691-693.
7. Chang YS, Chou YT, Lee JH, et al. Atopic dermatitis, melatonin, and sleep disturbance. Pediatrics. 2014;134(2):e397-e405.
8. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186-195.
9. Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-Analysis. BMJ. 2006;332(7538):385-393.
10. Brzezinski A, Vangel MG,Wurtman RJ, et al. Effects of exogenous melatonin on sleep: ameta-Analysis. Sleep Med Rev. 2005;9(1):41-50.
11. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.
12. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005;9(1):25-39.
13. Haldar C, Ahmad R. Photoimmunomodulation and melatonin. J Photochem Photobiol B. 2010; 98(2):107-117.
14. Radogna F, DiederichM, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol. 2010;80(12):1844-1852.
15. Marseglia L, D'Angelo G, Manti S, et al. Melatonin and atopy: role in atopic dermatitis and asthma. Int J Mol Sci. 2014;15(8):13482-13493.
16. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-Analysis. Dev Med Child Neurol. 2011;53(9): 783-792.
17. World Medical Association.World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053.
18. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31.
19. Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol. 2011;41:149-155.
20. Kovács J, BrodnerW, Kirchlechner V, Arif T, Waldhauser F. Measurement of urinary melatonin: a useful tool for monitoring serum melatonin after its oral administration. J Clin Endocrinol Metab. 2000;85(2):666-670.
21. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res. 1998;24 (4):230-238.
22. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44(1):57-64.
23. Weiss MD,Wasdell MB, Bomben MM, Rea KJ, Freeman RD. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J AmAcad Child Adolesc Psychiatry. 2006;45(5):512-519.
24. Van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J AmAcad Child Adolesc Psychiatry. 2007;46(2):233-241.
25. Kelsay K. Management of sleep disturbance associated with atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):198-201.
26. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol. 2002;22(5):511-515.
27. Levander S, Stahle-Bäckdahl M, Hägermark O. Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine. Eur J Clin Pharmacol. 1991;41(5):435-439.
28. García-Mauriño S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res. 2000;29(3):129-137.
29. Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation. 2008;15(2):93-101.
30. Moore CB, Siopes TD. Melatonin can produce immunoenhancement in Japanese quail (Coturnix coturnix japonica) without prior immunosuppression. Gen Comp Endocrinol. 2002; 129(2):122-126.
31. García JJ, López-Pingarrón L, Almeida-Souza P, et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res. 2014; 56(3):225-237.
32. Muñoz-Hoyos A, Espín-Quirantes C, Molina-Carballo A, et al. Neuroendocrine and circadian aspects (melatonin and -endorphin) of atopic dermatitis in the child. Pediatr Allergy Immunol. 2007;18(8):679-686.
33. Cikler E, Ercan F, Cetinel S, Contuk G, Sener G. The protective effects of melatonin against water avoidance stress-induced mast cell degranulation in dermis. Acta Histochem. 2005;106(6):467-475.
34. Kim TH, Jung JA, Kim GD, et al. Melatonin inhibits the development of 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice. J Pineal Res. 2009;47(4):324-329.